

IDEA Workshop on QRA based on NAMs: Building Trust December 10, 2019

The Dominican Hotel Rue Léopold 9, 1000 Brussels, Belgium Meeting Room: Salon II and III Final Draft Agenda 18-11-2019

Background

In the effort towards a QRA on skin sensitization based on new approach methodologies (NAMs) instead of the LLNA, IDEA provides a multi-stakeholder forum to facilitate the generation of a guidance framework based on NAMs to identify a NESIL for fragrance ingredients (FIs).

Such a framework should focus on deriving a continuous point of departure (PoD) from which the NESIL will be confirmed. This work should be complementary to the achievements that other organizations have already accomplished or activities that they are currently pursuing. The framework should rely on current existing methods and approaches but be open to new methods addressing specific gaps that IDEA perceives exist in current methodologies.

Previous IDEA workshops have focused on the available in vitro tests and the results obtained with them. A key need identified was a benchmark reference chemical potency list for the evaluation of NAMs, which would initially at least be focused on FIs. The workshops also helped identify questions that require attention in the process of building trust in NESILs derived from NAM data.

The aim of this workshop is to start building on the elements already identified previously as being key for confidence assessment of a framework for NESIL identification based on NAMs.

<u>Note:</u> Experts should bring their view of the issue and include in their presentation a discussion of questions listed below, as far as they have a view on them. Each of the agenda items below should constitute a short-focused presentation on 'state of the art' in those subjects followed by a discussion before moving to the next item of the agenda

9.00 – 9.15 Opening of and introduction into the WS by Hans Bender (IDEA Moderator) and Ian Kimber (Member IDEA Supervisory Group, Rapporteur of the WS)

9.15 – 9.45 Viable metabolic systems and how to assess pro-haptens with NAMs– Summary of the prohaptens workshop and outline of some key criteria to be fulfilled to build confidence in the use of NAM's Speaker: David Basketter, for Prof Jim Bridges, Chair of IDEA SG

9.45 – 10.15 Quality assurance in NAMs (cell viability, cell source, positive controls) and limitations for materials with limited solubility – How are these currently addressed?

A summary will be provided how the mentioned parameters are standardized within the current protocols (guidelines 442c, 442d and 442e), and practical experience is shown from extensive testing in the case of KeratinoSens and DPRA (442D and 442 C).

Speaker: Andreas Natsch, Givaudan

IDEA Management Team Avenue des Arts, 6 1210 Brussels, Belgium Tel: +32-2 214 20 61 Fax: +32-2 214 20 69 www.ideaproject.info



10.15 – 10.30 Coffee break

10.30 – 11.15 Confidence Assessment

How are the variability and knowledge gaps addressed in the LLNA and current DAs – what could be done and learnt for quantifying and managing uncertainty? **Speaker: Roman Liska, JRC**

Speaker: Roman Liska, JRC

11.15 – 12.00 Case studies showing identification of NESIL with NAMs by RIFM

Three to four detailed case studies as follows

- a. Case studies based only on in vitro/in silico data which were discordant (no read-across used), or
- b. Case studies with read-across which included human/animal data and in vitro/in silico data that were discordant.

Speaker: Anne Marie Api, RIFM

12.00 – 12.45 Weight of individual parameters measured in NAMs: meta-analysis and how it can be applied to NESIL determination – including case Studies

The presentation will address to which extent the different in vitro parameters correlate to LLNA potency – and how we can use that information to derive a NESIL and how we can look at uncertainty **Speaker: Andreas Natsch, Givaudan**

12.45 - 13.30 Lunch

13.30 – 14.15 Criteria that should be applied to a reference chemical potency list for FIs. What's left to be done?

Proposal to be presented and to be refined at the workshop, proposal will include two workflows: a) which chemicals to select based on their use in fragrance and based on animal and/or human data availability and b) workflow to define a WOE NESIL based on animal and human data

Speaker: Amaia Irizar, IFRA

14.15 – 15.15 General discussion

Objective is to identify the priorities for IDEA moving forward:

• Do we need to establish action subgroups to carry out some of the elements identified (e.g. Reference chemical potency list/ Drafting overarching guidance framework)?

• Is there a topic IDEA should pick to expand on in a subsequent separate workshop, like it's been done with pro-haptens (e.g. analyzing weight of evidence/ NAMs in support of Read-across for skin sensitization – building an IATA case study for OECD review)?

Moderated by Hans Bender

15.15 - 15.30 Coffee break

15.30 – 16.30 Key conclusions Moderated by Hans Bender

16.30 Closure of the workshop by Hans Bender and Ian Kimber